Palisade Bio Presents New Data for PALI-2108 at UEG Week 2026

Palisade Bio presented new clinical and translational data for its oral PDE4 inhibitor prodrug, PALI-2108, at the UEG Week 2026 conference. The data suggests potential for rapid endoscopic improvement in patients with inflammatory bowel disease, enhancing the therapeutic profile of the company's lead pipeline asset. This update reflects the company's ongoing research and development efforts in the inflammatory disease sector.